Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study evaluating primary rat and human cell cultures
PubMed 23463748 · doi:10.1530/JME-12-0186
What was done
Researchers established primary thyroid cell cultures from rats and humans to examine GLP-1 receptor (GLP1R) expression using in situ hybridization, mRNA, and protein assays. They also measured functional responses—specifically calcitonin expression and release—after treating the cultures with the GLP1R agonists liraglutide and taspoglutide.
What was found
GLP1R expression was detected in primary rat C-cells but was undetectable at the mRNA and protein levels in primary human C-cells. Treatment with liraglutide and taspoglutide elicited a modest increase in calcitonin expression and release in rat cultures, whereas human thyroid cultures showed no functional response despite the presence of calcitonin-positive C-cells. No specific numbers, concentrations, or statistical values were reported in the abstract.
Why it matters
These findings provide mechanistic evidence that the thyroid C-cell proliferative effects and calcitonin increases induced by GLP1R agonists in rodents may not directly translate to humans due to the lack of functional GLP1R expression on healthy human C-cells.
Limits
The abstract reports no sample sizes, donor counts, drug concentrations, or quantitative effect sizes. In vitro culture models may not fully capture long-term in vivo tissue architecture, chronic drug exposure dynamics, or potential receptor expression in pre-malignant or diseased human thyroid tissue.
Cited by
- supports GLP-1 receptor agonist medications carry an FDA black box warning for thyroid cancer based on animal studies.